PYC Therapeutics Advances PYC-003 in Polycystic Kidney Disease Trial

An update from PYC Therapeutics Limited ( (AU:PYC) ) is now available.

PYC Therapeutics Limited has announced the dosing of the first subject in its Phase 1a clinical trial for PYC-003, a drug candidate aimed at treating Polycystic Kidney Disease (PKD). This trial marks a significant step in addressing PKD, a condition with no current treatment options, and if successful, could lead to a rapid approval process following a combined Phase 2/3 study. The trial will assess the safety and efficacy of PYC-003, with plans to escalate dosing and expand the study to include patients with PKD later in 2025.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases that currently have no available options. The company is engaged in three clinical-stage drug development programs, including PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD).

YTD Price Performance: -19.47%

Average Trading Volume: 532,563

Technical Sentiment Signal: Hold

Current Market Cap: A$564.7M

Learn more about PYC stock on TipRanks’ Stock Analysis page.